Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status

PURPOSE: Concurrent chemoradiotherapy (CCRT) is the standard care for stage III non-small cell lung cancer (NSCLC) patients; however, a more effective regimen is needed to improve the outcome by better controlling occult metastases. We conducted two parallel randomized phase II studies to incorporat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Youngjoo, Han, Ji-Youn, Moon, Sung Ho, Nam, Byung-Ho, Lim, Kun Young, Lee, Geon Kook, Kim, Heung Tae, Yun, Tak, An, Hye Jin, Lee, Jin Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654157/
https://www.ncbi.nlm.nih.gov/pubmed/28111430
http://dx.doi.org/10.4143/crt.2016.522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654157/
https://www.ncbi.nlm.nih.gov/pubmed/28111430
http://dx.doi.org/10.4143/crt.2016.522

Ejemplares similares